European Patent Office Maintains FibroGen Patent Relating to Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor Technology
05 juin 2017 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, June 05, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, announced today that a FibroGen European patent relating to the therapeutic...
FibroGen, Inc. Announces Pricing of Follow-On Offering of Common Stock
06 avr. 2017 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, April 06, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that the company has priced an underwritten follow-on...
FibroGen’s Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in China
30 janv. 2017 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, Jan. 30, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, and its subsidiary FibroGen China Medical Technology Development Co., Ltd....
FibroGen Reports Financial Results for the Third Quarter of 2016 and Provides Corporate Update
08 nov. 2016 16h03 HE
|
FibroGen, Inc.
– Completes Enrollment of Roxadustat Phase 3 Studies in China for Anemia in CKD – – Conference Call and Webcast to be Held Today at 4:30 p.m. Eastern Time/1:30 p.m. Pacific...
FibroGen to Report Third Quarter 2016 Financial Results on November 8, 2016
01 nov. 2016 17h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, Nov. 01, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel...
FibroGen to Report Second Quarter 2016 Financial Results on August 8, 2016
02 août 2016 20h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, Aug. 02, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel...
FibroGen Announces Receipt of $62 Million License Payment from AstraZeneca
08 juil. 2016 04h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, July 08, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq:FGEN) (“FibroGen”), a research-based biopharmaceutical company, announced today that it has received a scheduled $62 million...
FibroGen to Present at the Goldman Sachs 37th Annual Global Healthcare Conference
06 juin 2016 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, June 06, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), announced that Chief Executive Officer, Thomas B. Neff, will be presenting at the Goldman Sachs 37th Annual Global...
FibroGen Reports Financial Results for the First Quarter of 2016
09 mai 2016 16h02 HE
|
FibroGen, Inc.
Continued Progress in Roxadustat Phase 3 Studies; Promising Interim Pancreatic Cancer Data –Webcast Conference Call Scheduled for 4:30pm EST Today– SAN FRANCISCO, May 09, 2016 (GLOBE NEWSWIRE)...
FibroGen to Report First Quarter 2016 Financial Results on May 9, 2016
02 mai 2016 16h05 HE
|
FibroGen, Inc.
SAN FRANCISCO, May 02, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel...